Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non–small-cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience

Joint Mean-Variance Overall Survival Time fitted Models from Stage III Non-Small Cell Lung Cancer

“…The present result disagrees with the result in [16], but it agrees with the results, which have pointed that from a radiological point of views, shorter treatment (less than 28 days) can improve the mean OST of NSCLC patients [36,37]. It is also pointed in the earlier studies that a decrease in tumor control approximately 1.6% per day after a 6-week duration of radiation therapy, and approximately 2.0% increase in the risk of death for each day of prolongation in therapy [38]. Therefore, the present studies supports most of the earlier results regarding the overall treatment time.…”

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

“…W przypadku indukcyjnej chemioterapii krytycznym czynnikiem warunkującym skuteczność leczenia jest czas od zakończenia chemioterapii do rozpoczęcia radioterapii, bowiem pod wpływem chemioterapii dochodzi do przyspieszonej repopulacji komórek nowotworowych [68]. Dodanie indukcyjnej lub konsolidującej chemioterapii do równoczesnej radiochemioterapii nie ma wpły-wu na czas przeżycia, a równocześnie zwiększa toksyczność leczenia [69,70].…”

Gemcitabine, Cisplatin, and Hyperfractionated Accelerated Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

“…The reduction of the MTD in our trial corresponds to 1.3 as the factor of radiosensitization due to concurrent gemcitabine, a figure that compares well with the published data on gemcitabine-enhanced radiosensitivity. 25,26 A detailed look at the actual performance of our trial reveals four areas of criticism and, at the same time, of potential for improvement of results: staging, radiotherapy planning, attention to anemia, and small sample.…”